Roberto Lorbeer1,2, Sebastian E Baumeister3, Marcus Dörr4,5, Matthias Nauck5,6, Anne Grotevendt6, Sabrina Schlesinger7, Alexander Teumer1, Henry Völzke1,5, Hans-Jörgen Grabe8, Henri Wallaschofski6, Ramachandran S Vasan9, Wolfgang Lieb10. 1. Institute for Community Medicine, Section of Clinical Epidemiology, University Medicine, Ernst Moritz Arndt University Greifswald, Greifswald, Germany. 2. Institute of Clinical Radiology, Ludwig-Maximilian-University Hospital, Munich, Germany. 3. Department of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany. 4. Department of Internal Medicine B, University Medicine, Ernst Moritz Arndt University Greifswald, Greifswald, Germany. 5. DZHK (German Centre for Cardiovascular Research), Partner Site, Greifswald, Germany. 6. Institute of Clinical Chemistry and Laboratory Medicine, University Medicine, Ernst Moritz Arndt University Greifswald, Greifswald, Germany. 7. Institute of Epidemiology, Christian Albrecht University, Kiel, Germany. 8. Department of Psychiatry and Psychotherapy, University Medicine, Ernst Moritz Arndt University Greifswald, Greifswald, Germany. 9. Preventive Medicine & Epidemiology Section, Boston University School of Medicine and Framingham Heart Study, Framingham, Massachusetts, USA. 10. Institute of Epidemiology, Christian Albrecht University, Kiel, Germany. wolfgang.lieb@epi.uni-kiel.de.
Abstract
OBJECTIVE: Since angiopoietin-2 (Ang-2) levels strongly correlate with cardiovascular mortality and subclinical cardiovascular disease, it was hypothesized that levels of Ang-2 and its soluble receptor (sTie-2) were associated with the metabolic syndrome (MetS) and individual MetS components. METHODS: Within the population-based Study of Health in Pomerania, two sets of analyses were performed. First, Ang-2 and sTie-2 were related to the prevalence of MetS and its components cross-sectionally (n = 3,205). Second, the association between baseline Ang-2 and sTie-2 and incident MetS or longitudinal changes in its components in 1,295 individuals was investigated. RESULTS: High Ang-2 levels (90th percentile), compared with low Ang-2 levels (10th percentile), were positively associated with MetS (OR: 1.78) and with the following MetS criteria: increased triglycerides, lower HDL cholesterol, and higher non-fasting glucose. Furthermore, high sTie-2 levels (90th percentile), compared with low levels (10th percentile), were positively related to MetS (OR: 1.58) and most of its components. However, Ang-2 and sTie-2 levels were not associated with incident MetS or longitudinal change in components of MetS. CONCLUSIONS: Ang-2 and sTie-2 levels were cross-sectionally associated with MetS and several of its components. However, Ang-2 and sTie-2 levels were not associated with incident MetS or changes in individual MetS components during follow-up.
OBJECTIVE: Since angiopoietin-2 (Ang-2) levels strongly correlate with cardiovascular mortality and subclinical cardiovascular disease, it was hypothesized that levels of Ang-2 and its soluble receptor (sTie-2) were associated with the metabolic syndrome (MetS) and individual MetS components. METHODS: Within the population-based Study of Health in Pomerania, two sets of analyses were performed. First, Ang-2 and sTie-2 were related to the prevalence of MetS and its components cross-sectionally (n = 3,205). Second, the association between baseline Ang-2 and sTie-2 and incident MetS or longitudinal changes in its components in 1,295 individuals was investigated. RESULTS: High Ang-2 levels (90th percentile), compared with low Ang-2 levels (10th percentile), were positively associated with MetS (OR: 1.78) and with the following MetS criteria: increased triglycerides, lower HDL cholesterol, and higher non-fasting glucose. Furthermore, high sTie-2 levels (90th percentile), compared with low levels (10th percentile), were positively related to MetS (OR: 1.58) and most of its components. However, Ang-2 and sTie-2 levels were not associated with incident MetS or longitudinal change in components of MetS. CONCLUSIONS:Ang-2 and sTie-2 levels were cross-sectionally associated with MetS and several of its components. However, Ang-2 and sTie-2 levels were not associated with incident MetS or changes in individual MetS components during follow-up.
Authors: Katarzyna M Terlikowska; Bozena Dobrzycka; Robert Terlikowski; Anna Sienkiewicz; Maciej Kinalski; Slawomir J Terlikowski Journal: BMC Cancer Date: 2020-09-25 Impact factor: 4.430